Degenerate binding of tyrosinase peptides to MHC II Ad/Ed molecules

Journal of Experimental Therapeutics and Oncology

Volumn 6, Issue 3, 2007, Pages 231-239

  Mittelman, Abraham ^a   Lucchese, Guglielmo ^a   Stufano, Angela ^a   Kanduc, Darja ^a,b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

MHC binding potential; Peptide immunogenicity; Receptor ligand binding; Tyrosinase peptides

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOPHENOL MONOOXYGENASE; PEPTIDE;

AMINO ACID SEQUENCE; ANTIBODY AFFINITY; ARTICLE; BINDING ASSAY; ENZYME BINDING; GEL MOBILITY SHIFT ASSAY; MOLECULE; PREDICTION; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; BLOTTING, WESTERN; CELL LINE; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENES, MHC CLASS II; LYMPHOCYTES; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; MONOPHENOL MONOOXYGENASE; PEPTIDES; PROTEIN BINDING;

EID: 34249008060     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature 334: 395-402, 1988.
2. Evavold BD, Williams SG, Hsu BL, Buus S, Allen PM. Complete dissection of the Hb (64-76) determinant using T helper 1, T helper 2 clones, and T cell hybridomas. J Immunol 148:347-353, 1992.
3. Evavold BD, Sloan-Lancaster J, Allen PM. Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands. Immunol Today 14:602-609, 1993.
4. Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76:287-299, 1994.
5. Krensky AM, Clayberger C. The induction of tolerance to alloantigens using HLA-based synthetic peptides. Curr Opin Immunol 6:791-796, 1994.
6. Madden DR. The three-dimensional structure of peptide-MHC complexes. Annu Rev Immunol 13:587-622, 1995.
7. McDevitt HO. Discovering the role of the major histocompatibility complex in the immune response. Annu Rev Immunol 18:1-17, 2000.
8. Rudolph MG, Wilson IA. The specificity of TCR/pMHC interaction. Curr Opin Immunol 14:52-65, 2002.
9. Rogers PR, Grey HM, Croft M. Modulation of naive CD4 T cell activation with altered peptide ligands: the nature of the peptide and presentation in the context of costimulation are critical for a sustained response. J Immunol 160: 3698-3704, 1998.
10. Rothbard JB, Gefter ML. Interactions between immunogenic peptides and MHC proteins. Annu Rev Immunol 9: 527-565, 1991.
11. Figueredo Dos Santos C, Tilkin-Mariame AF, De Preval C, Lakhdar-Ghazal F. Influence of histidine beta81 of HLA-DR101 on peptide binding and presentation to T-cell receptor. Hum Immunol 63:459-466, 2002.
12. Fuller TC, Fuller A. The humoral immune response against an HLA class I allodeterminant correlates HLA-DR phenotype of the responder. Transplantation 68: 173-182, 1999.
13. Schuenke KW, Cook RG, Rich RR. Binding specificity of a class II-restricted hepatitis B epitope by DR molecules from responder and nonresponder vaccine recipients. Hum Immunol 59: 783-793, 1998.
14. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Willey DC. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 329:512-518, 1987.
15. Buus S, Sette A, Colon SM, Miles C, Grey HM. The relation between major histocompatibility complex restriction and the capacity of Ia to bind immunogenic peptides. Science 235:1353-1358, 1987.
16. Garrett TPJ, Saper MA, Bjorkman PJ, Strominger JL, Wiley DC. Specificity pockets for the side chains of peptide antigens in HLA-Aw68. Nature 342:692-696, 1989.
17. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74:929-937, 1993.
18. Salazar LG, Fikes J, Southwood S, Ishioka G, Knutson KL, Gooley TA, Schiffman K, Disis ML. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res 9: 5559-5565, 2003.
19. Sinigaglia F, Hammer J. Motifs and supermotifs for MHC class II binding peptides. J Exp Med 181:449-451, 1995.
20. Brusic V, Petrovsky N, Zhang G, Bajic V. Prediction of promiscuous peptides that bind HLA class I molecules. Immunol Cell Biol 80:280-285, 2002.
21. Brusic V, Rudy G, Honeyman G, Hammer J, Harrison L. Prediction of MHC-class-II-binding peptides using an evolutionary algorithm and artificial neural network. Bioinformatics 14:121-130, 1998.
22. Jung G, Fleckenstein B, von der Mülbe F, Wessels J, Niethammer D, Wiesmüller KH. From combinatorial libraries to MHC ligand motifs, T-cell superagonists and antagonists. Biologicals 29:179-181, 2001.
23. Kwok WW, Gebe JA, Liu A, Agar S, Ptacek N, Hammer J, Koelle DM, Nepom G T. Rapid epitope identification from complex class-II-restricted T-cell antigens. Trends Immunol 22:583-588, 2001.
24. Natale C, Giannini T, Lucchese A, Kanduc D. Computer-assisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences. Immunol Cell Biol 78:580-585, 2000.
25. Rammensee HG, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPE1TH1: database for MHC ligands and peptide motifs. Immunogenetics 50:213-219, 1999.
26. Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin U, Braxenthaler M, Gallazzi F, Protti MP, Sinigaglia F, Hammer J. Generation of tissue-specific, promiscuous HLA ligand databases using DNA microarrays virtual HLA class II matrices. Nature Biotech 17:555-561, 1999.
27. Yu K, Petrovsky N, Schonbach C, Koh JY, Brusic V. Methods for prediction of peptide binding to MHC molecules: a comparative study. Mol Med 8:137-148, 2002.
28. Lucchese A, Mittelman A, Lin MS, Kanduc D, Sinha AA. Epitope definition by proteomic similarity analysis: identification of the linear determinant of the anti-Dsg3 MAb 5H10. J Transl Med 2: 43, 2004.
29. Lucchese A, Stevanovic S, Sinha AA, Mittelman A, Kanduc D. Role of MHC II affinity and molecular mimicry in defining anti-HER-2/neu MAb-3 linear peptide epitope. Peptides 24:193-197, 2003.
30. Tiwari R, Geliebter J, Lucchese A, Mittelman A, Kanduc D. Computational peptide dissection of Melan-a/MART-1 oncoprotein antigenicity. Peptides 25: 1865-1871, 2004.
31. Reche PA, Glutting JP, Reinherz EL. Prediction of MHC Class I binding peptides using profile motifs. Hum Immunol 63:701-709, 2002.
32. Reche PA, Glutting JP, Zhang H, Reinherz EL. Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics 456:405-419, 2004.
33. Willers J, Lucchese A, Mittelman A, Dummer R, Kanduc D. Definition of anti-tyrosinase MAb T311 linear determinant by proteome-based similarity analysis. Exp Dermatol 14:543-550, 2005.
34. Ozato K, Sachs DH. Monoclonal antibodies to mouse MHC antigens. III. Hybridoma antibodies reacting to antigens of the H-2b haplotype reveal genetic control of isotype expression. J Immunol 126:317-321, 1981.
35. Falk K, Rötzschke O, Stevanovic S, Jung G, Rammensee HG. Allele specific motifs revealed by sequencing of self peptides eluted from MHC molecules. Nature 351:290-296, 1991.
36. Rammensee HG, Friedle T, Stevanovic S. MHC ligands and peptide motifs: first listing. Immunogenetics 41:178-228, 1995.
37. Belmares MP, Busch R, Wucherpfennig KW, McConnell HM, Mellins ED. Structural factors contributing to DM susceptibility of MHC class II/peptide complexes. J Immunol 169:5109-5117, 2002.
38. Ferlin WG, Mougneau E, Hugues S, Appel H, Jang MH, Cazareth J, Beaudoin L, Schricke C, Lehuen A, Wucherpfennig KW, Glaichenhaus N. Self-peptides that bind with low affinity to the diabetes-associated I-A(g7) molecule readily induce T cell tolerance in non-obese diabetic mice. Eur J Immunol 34:2656-2663, 2004.
39. Kozhich AT, Caspi RR, Berzofsky JA, Gery I. Immunogenicity and immunopathogenicity of an autoimmune epitope are potentiated by increasing MHC binding through residue substitution. J Immunol 158:4145-4151, 1997.
40. Madden DR, Gorga JC, Strominger JL, Wiley DC. The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation. Nature 353:321-325, 1991.
41. Sette A, Sidney J, Oseroff C, del Guercio MF, Southwood S, Arrhenius T, Powell MF, Colon SM, Gaeta FC, Grey HM. HLA DR4w4-binding motifs illustrate the biochemical basis of degeneracy and specificity in peptide-DR interactions. J Immunol 151:3163-3170, 1993.
42. Sette A, Sidney J. HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr Opin Immunol 10:478-82, 1998.
43. Li Y, Li H, Martin R, Mariuzza RA. Structural basis for the binding of an immunodominant peptide from myelin basic protein in different registers by two HLA-DR2 proteins. J Mol Biol 304:177-188, 2000.
44. Lucchese A, Willers J, Mittelman A, Kanduc D, Dummer R. Proteomic scan for tyrosinase peptide antigenic pattern in vitiligo and melanoma: role of sequence similarity and HLA-DR1 affinity. J Immunol 175:7009-7020, 2005.
45. Sinha AA, Lopez MT, McDevitt HO. Autoimmune diseases: the failure of self tolerance. Science 248:1380-1388, 1990.
46. Threlkeld SC, Wentworth PA, Kalams SA, Wilkes BM, Ruhl DJ, Keogh E, Sidney J, Southwood S, Walker BD, Sette A. Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class I A3-like superfamily: implications for vaccine development. J Immunol 159:1648-1657, 1997.
47. Del Guercio MF, Sidney J, Hermanson G, Perez C, Grey HM, Kubo RT, Sette A. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J Immunol 154:685-693, 1995.
48. Fleischhauer K, Tanzarella S, Wallny HJ, Bordignon C, Traversari C. Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201 cytotoxix T cell line. J Immunol 157:787-797, 1996.
49. Godkin AJ, Smith KJ, Willis A, Tejada-Simon MV, Zhang J, Elliott T, Hill AV. Naturally processed HLA class II peptides reveal highly conserved immunogenic flanking region sequence preferences that reflect antigen processing rather than peptide-MHC interactions. J Immunol 166:6720-6727, 2001.
50. Levitsky V, Liu D, Southwood S, Levitskaya J, Sette A, Masucci MG. Supermotif peptide binding and degeneracy of MHC: peptide recognition in an EBV peptide-specific CTL response with highly restricted TCR usage. Hum Immunol 61:972-984, 2000.
51. Vidal K, Daniel C, Vidavsky I, Nelson CA, Allen PM. Hb(64-76) epitope binds in different registers and lengths to I-Ek and I-Ak. Mol Immunol 37:203-212, 2000.
52. He X, Tabaczewski P, Ho J, Stroynowski I, Garcia KC. Promiscuous antigen presentation by the nonclassical MHC Ib Qa-2 is enabled by a shallow, hydrophobic groove and self-stabilized peptide conformation. Structure 9:1213-1224, 2001.
53. Joshi SK, Suresh PR, Chauhan V S. Flexibility in MHC and TCR recognition: degenerate specificity at the T cell level in the recognition of promiscuous Th epitopes exhibiting no primary sequence homology. J Immunol 166:6693-6703, 2001.
54. Lee KH, Wang E, Nielsen MB, Wundderlich J, Migueles S, Connors M, Steinberg SM, Rosenberg SA, Marincola FM. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 163:6292-6300, 1999.
55. Maverakis E, van den Elzen P, Sercarz EE. Self-reactive T cells and degeneracy of T cell recognition: evolving concepts-from sequence homology to shape mimicry and TCR flexibility. J Autoimmun 16:201-209, 2001.
56. Murray JS, Fois SD, Schountz T, Ford SR, Tawde MD, Brown JC, Siahaan TJ. Modeling alternative binding registers of a minimal immunogenic peptide on two class II major histocompatibility complex (MHC II) molecules predicts polarized T-cell receptor (TCR) contact positions. J Pept Res 59:115-122, 2002.
57. Andersen ML, Ruhwald M, Nissen MH, Buus S, Claesson MH. Self-peptides with intermediate capacity to bind and stabilize MHC class I molecules may be immunogenic. Scand J Immunol 57:21-27, 2003.
58. Pisarev VM, Kinarsky L, Caffrey T, Hanisch FG, Sanderson S, Hollingsworth MA, Sherman S. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1. Int Immunopharmacol 5:315-330, 2005.
59. Pelte C, Cherepnev G, Wang Y, Schoenemann C, Volk HD, Kern F. Random screening of proteins for HLA-A*0201-binding nine-amino acid peptides is not sufficient for identifying CD8 T cell epitopes recognized in the context of HLA-A*0201. J Immunol 172:6783-6789, 2004.